Classical psychedelics for the treatment of depression and anxiety: A systematic review

Background: Depression and anxiety are prevalent psychiatric disorders that carry significant morbidity. Pharmacological and psychosocial interventions are used to manage these conditions, but their efficacy is limited. Recent interest into the use of psychedelic-assisted therapy using ayahuasca, psilocybin or lysergic acid diethylamide (LSD) may be a promising alternative for patients unresponsive to traditional treatments. This review […]

A review of the clinical effects of psychotomimetic agents

We are using Gerard’s term “psychotomimetics” generically for compounds that have been called schizogens, psychotica, psychotogens, phantastica, hallucinogens, and elixirs. If one believes that the importance of these compounds lies in their capacity to mimic the mental illnesses called psychoses, psychotomimetics would be  the term of choice. This capacity alone would make these drugs the […]

Entheogens and psychedelics in Canada: Proposal for a new paradigm

After decades of prohibition, scientific and academic inquiry into the psychedelic sciences has been reignited in the West. Alongside research, clinicians are being permitted to study the effects of psychedelic substances in humans, and the door has been opened to deliver psychedelic-assisted therapies for mental health needs. However, despite excitement for the professional use of […]

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims: The aim […]